On December 13, 2005, Siskinds filed a class proceeding against Pfizer Canada Inc. and Pfizer Inc. with respect to Depo-Provera. Depo-Provera is typically prescribed to prevent pregnancy, however, it is also used to treat endometriosis and as a palliative treatment of certain cancers. Use of Depo-Provera has been associated with an increased risk of significant bone mineral density loss, including a significantly increased risk of developing osteoporosis at ages below the statistical norm.
On May 28, 2008, the Superior Court of Quebec certified the action as a National Class. Any person who has taken Depo-Provera and has been affected with bone mineral density loss is part of the defined class.
Siskinds is working cooperatively with the Quebec firm of Belleau Lapointe LLP
For further information concerning this action, please contact Jennifer Bald at 1-800-461-6166 ext. 2455 or email Jennifer.Bald@Siskinds.com.
 Back to Siskinds Actions
|
